Ahead of IPO, Corona Remedies Acquires 7 Key Brands from Bayer to Boost Pharma Portfolio

Ahmedabad-based Corona Remedies has made a strategic leap ahead of its public listing by acquiring a portfolio of seven brands from Bayer’s pharmaceutical business in India. The acquisition, effective from 16th July 2025, enhances the company’s therapeutic offerings across two major categories of cardiology and women’s healthcare, which reflects its ongoing focus on building a robust brand mix through MNC partnerships.

Stronger Presence in High-Growth Segments

The deal marks Corona’s entry into the anti-platelet monotherapy segment with the addition of the Noklot brand. This segment, currently valued at ₹1,507 crore, is expanding at an annual growth rate of 8%. 

Alongside, the acquisition brings six women’s healthcare brands — Fostine, Luprofact, Menodac, Ovidac, Spye and Vageston into Corona’s fold. These brands enhance their footprint in the Gonadotrophin and Progesterone Hormone market, which was valued at ₹1,862 crore as of MAT June 2025.

Fourth Acquisition from Global Majors

Corona Remedies has not disclosed the deal size but confirmed it as its fourth brand acquisition from global pharmaceutical companies. Previous transactions involved well-known players such as Sanofi, GlaxoSmithKline, and Abbott India. 

The company’s acquisition-led growth strategy reflects a consistent approach to strengthening its domestic portfolio ahead of its IPO(initial public offering). It had filed its Draft Red Herring Prospectus with SEBI in April 2025.

Also Read: Emcure Pharma Signs Distribution Deal with Sanofi India!

Conclusion

With the addition of Bayer’s established brands, Corona Remedies is bolstering its market reach in two important therapy areas. The move not only signals its readiness for the IPO market but also reinforces its long-term commitment to building a diversified and specialised pharmaceutical portfolio.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.